Janney Montgomery Scott LLC Sells 2,887 Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Posted by Defense World Staff on Nov 2nd, 2023

Janney Montgomery Scott LLC cut its stake in Horizon Therapeutics Public Limited (NASDAQ:HZNP – Free Report) by 45.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,401 shares of the biopharmaceutical company’s stock after selling 2,887 shares during the period. Janney Montgomery Scott LLC’s holdings in Horizon Therapeutics Public were worth $350,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. TFC Financial Management Inc. bought a new position in Horizon Therapeutics Public during the 1st quarter worth about $25,000. Global Retirement Partners LLC grew its holdings in Horizon Therapeutics Public by 156.4% during the 2nd quarter. Global Retirement Partners LLC now owns 241 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 147 shares in the last quarter. Ameritas Advisory Services LLC bought a new position in Horizon Therapeutics Public during the 1st quarter worth about $31,000. Samalin Investment Counsel LLC bought a new position in Horizon Therapeutics Public during the 1st quarter worth about $41,000. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Horizon Therapeutics Public by 209.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 433 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 293 shares in the last quarter. 80.37% of the stock is currently owned by institutional investors.

Horizon Therapeutics Public Stock Performance

Shares of Horizon Therapeutics Public stock opened at $116.30 on Thursday. The firm has a market capitalization of $26.63 billion, a P/E ratio of 62.19, a PEG ratio of 3.96 and a beta of 1.03. The company has a quick ratio of 4.09, a current ratio of 4.27 and a debt-to-equity ratio of 0.48. The company has a 50 day moving average price of $115.25 and a 200 day moving average price of $107.83. Horizon Therapeutics Public Limited has a 52 week low of $60.03 and a 52 week high of $116.38.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Free Report) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.08. Horizon Therapeutics Public had a net margin of 12.02% and a return on equity of 20.46%. The company had revenue of $945.00 million during the quarter, compared to analyst estimates of $873.52 million. During the same period last year, the firm posted $1.07 EPS. Horizon Therapeutics Public’s revenue for the quarter was up 7.8% compared to the same quarter last year. Sell-side analysts expect that Horizon Therapeutics Public Limited will post 4.19 EPS for the current year.

Analysts Set New Price Targets

HZNP has been the topic of a number of recent analyst reports. StockNews.com initiated coverage on shares of Horizon Therapeutics Public in a report on Wednesday. They issued a “strong-buy” rating on the stock. Jefferies Financial Group cut shares of Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Seven research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $116.83.

Check Out Our Latest Research Report on HZNP

Horizon Therapeutics Public Company Profile

(Free Report)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.